BioCryst Pharmaceuticals, Inc.
BCRX
$7.40
$0.182.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -88.88M | -123.82M | -145.93M | -208.59M | -226.54M |
| Total Depreciation and Amortization | 3.01M | 2.57M | 2.68M | 2.77M | 2.87M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 121.13M | 123.37M | 124.30M | 157.77M | 160.93M |
| Change in Net Operating Assets | -87.28M | -57.85M | -64.92M | -53.27M | -32.40M |
| Cash from Operations | -52.02M | -55.73M | -83.87M | -101.31M | -95.14M |
| Capital Expenditure | -1.12M | -1.00M | -1.93M | -2.24M | -2.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.72M | 7.33M | 22.88M | 6.61M | -129.33M |
| Cash from Investing | 52.59M | 6.32M | 20.95M | 4.37M | -131.50M |
| Total Debt Issued | -- | 0.00 | 0.00 | 300.00M | 300.00M |
| Total Debt Repaid | -1.70M | -2.51M | -1.96M | -242.01M | -241.62M |
| Issuance of Common Stock | 4.06M | 4.22M | 3.62M | 5.30M | 8.68M |
| Repurchase of Common Stock | -581.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.54M | -6.62M | -6.62M | -36.93M | -34.58M |
| Cash from Financing | -5.76M | -4.91M | -4.96M | 26.36M | 32.49M |
| Foreign Exchange rate Adjustments | -936.00K | 890.00K | 292.00K | 118.00K | 362.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.12M | -53.43M | -67.58M | -70.47M | -193.79M |